KCNK17

KCNK17 encodes K2P17.1 (TALK-2/TASK-4), a two-pore-domain background potassium channel that sets resting membrane potential and is gated by alkaline extracellular pH (via a pore-loop lysine), reactive oxygen and nitrogen species, and pharmacological agents including propafenone (PMID:15513946, PMID:29753045, PMID:30008082). The channel operates through two positively coupled gates — a selectivity filter gate and a cytoplasmic lower gate — whose allosteric linkage ensures that stimuli opening one gate facilitate opening of the other (PMID:39215031). K2P17.1 heterodimerizes with TASK-1 to produce channels with hybrid pH and anesthetic sensitivities, and localizes to both the plasma membrane and the endoplasmic reticulum membrane of pancreatic beta cells, where ER-resident channels drive Ca²⁺ leak from ER stores to promote basal insulin secretion while limiting glucose-stimulated secretion (PMID:29016681, PMID:41739147). A gain-of-function G88R mutation confers dominant-active enhancement of K⁺ current, hyperpolarizes and slows action potential upstroke in cardiomyocytes, and is linked to cardiac arrhythmia (PMID:24972929).

1. 2004 High

   Identifying the stimuli that gate K2P17.1 was essential; demonstrating that nitric oxide, superoxide, and singlet oxygen each robustly activate the channel established ROS/RNS as direct modulators, distinguishing TALK-2 from other K2P family members.

   Evidence Two-electrode voltage clamp in Xenopus oocytes with multiple ROS/RNS donors and appropriate controls

   PMID:15513946

   Open questions at the time

   • Molecular target residue(s) for ROS/RNS modification not identified
   • Physiological relevance of ROS activation not tested in native tissues
2. 2014 High

   Linking a specific mutation to disease required showing that G88R increases K⁺ current threefold without altering surface expression and acts dominant-actively, thereby hyperpolarizing cardiomyocytes — establishing a gain-of-function mechanism for arrhythmia.

   Evidence Whole-exome sequencing, two-electrode voltage clamp in oocytes, surface expression assay, and action potential recordings in HL-1 cardiomyocytes

   PMID:24972929

   Open questions at the time

   • No in vivo animal model to confirm arrhythmogenicity
   • Structural basis of G88R-mediated conductance increase unknown
3. 2017 High

   Whether K2P channels from different subfamilies can heterodimerize was unresolved; demonstrating that TALK-2 and TASK-1 form functional heterodimers with hybrid pharmacological properties expanded the combinatorial diversity of background K⁺ currents.

   Evidence Single-molecule TIRF, BiFC, FRET, and whole-cell patch clamp in pancreatic cell line and HEK293 cells

   PMID:29016681

   Open questions at the time

   • Stoichiometry and structure of the heterodimer not determined
   • Native tissue abundance of heterodimer versus homodimer not quantified
4. 2018 High

   The pharmacological profile of K2P17.1 was largely uncharacterized; showing activation by propafenone, quinidine, and mexiletine and inhibition by amiodarone and verapamil revealed that common antiarrhythmic drugs directly modulate the channel, with potential clinical implications for patients carrying gain-of-function variants.

   Evidence Two-electrode voltage clamp in oocytes and whole-cell patch clamp in CHO cells

   PMID:30008082

   Open questions at the time

   • Drug binding sites on the channel not mapped
   • In vivo relevance of drug-channel interactions at therapeutic concentrations not established
5. 2018 Medium

   The molecular basis of alkaline pH activation was clarified by cross-species comparison: zebrafish K2P17.1 lacks the pore-loop lysine present in the human channel and is pH-insensitive, pinpointing this residue as the pH sensor.

   Evidence Electrophysiology in oocytes and sequence alignment identifying critical lysine

   PMID:29753045

   Open questions at the time

   • Lysine mutant in human channel not directly tested in this study
   • Mechanism by which lysine protonation state alters conductance not elucidated
6. 2024 High

   Whether K2P17.1 possesses a functional lower gate was unknown; demonstrating a cytoplasmic gate that is positively coupled to the selectivity filter gate — with each gate's opening facilitating the other — revealed a dual-gate allosteric mechanism governing channel activity.

   Evidence Electrophysiology with fast cysteine modification (MTSET accessibility), pharmacological and lipid modulation, and pore-cysteine mutagenesis

   PMID:39215031

   Open questions at the time

   • Structural basis of gate coupling not resolved at atomic level
   • Whether heterodimeric channels with TASK-1 share the same coupling mechanism is unknown
7. 2026 High

   K2P17.1 was assumed to function only at the plasma membrane; showing that it also resides on the ER membrane where it drives K⁺ flux that enhances ER Ca²⁺ leak, thereby elevating basal Ca²⁺ and promoting basal insulin secretion while dampening glucose-stimulated secretion, established a novel intracellular function.

   Evidence Co-localization with ER markers, ER membrane potential sensing, cytoplasmic and ER Ca²⁺ measurements, and insulin secretion assays in an inducible cell line and primary human beta cells with shRNA knockdown

   PMID:41739147

   Open questions at the time

   • How K2P17.1 is trafficked to and retained in the ER membrane is unknown
   • Whether ER-localized K2P17.1 function is relevant in non-beta-cell types is untested
   • Relative contribution of ER versus plasma membrane channels to beta-cell physiology not quantified

• A high-resolution structure of K2P17.1 — either as homodimer or TASK-1 heterodimer — is lacking, leaving the structural basis of dual-gate coupling, ROS sensing, pH sensing, and drug modulation unresolved.
• No cryo-EM or crystal structure available
• ROS/RNS-sensing residues not identified by mutagenesis
• In vivo cardiac phenotype of G88R not modeled in animals